Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

CAPS Rating: 4 out of 5

A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options.

Recs

0
Player Avatar Zhraath (48.09) Submitted: 5/7/2012 1:39:40 PM : Outperform Start Price: $10.61 SPPI Score: -65.77

it's highly unlikely that a cancer patient will switch to the generic alternative. This has to be the most undervalued stock I've seen in a long time.

Featured Broker Partners


Advertisement